Vol. 5 (12) pp. 184-192 DOI: 10.21474/IJAR01/5954

SERUM GOLGI PROTEIN 73 IN PATIENTS WITH HEPATOCELLULAR CARCINOMA.

, , and
  • Department of Hepatology, Gastroenterology and Infectious diseases, Faculty of Medicine, Benha University.
  • Department of Clinical pathology, Faculty of Medicine, Benha University.
  • Department of Hepatology, Gastroenterology and Infectious diseases, Ministry of health.
10 Downloads 109 Views
Crossref

Download Full Paper (PDF)

Abstract

Background: Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide. The diagnosis of HCC is mainly based on a combination of abdominal ultrasound and serum alpha fetoprotein (AFP) level. Serum AFP has low sensitivity, serum Golgi protein 73 (sGP73) is a novel and promising biomarker for detection of hepatocellular carcinoma (HCC). However, there are few reports on the predictive values levels of GP73 in diagnosis of HCC. We aimed to evaluate the clinical usefulness of serum GP73 in the diagnosis of HCC. Methods: The study was conducted on 80 patients included 20 patients with chronic hepatitis C (group I), 20 patients with liver cirrhosis (group II divided into two subgroups of equal number compensated and decompensated liver cirrhosis), 40 patients with HCC (group III) in addition to 10 apparently healthy control subjects (group IV). All patients in this study were subjected to full history taking, thorough clinical examination, radiological investigations, routine laboratory investigations and serum AFP in addition to serum GP73 assay by ELISA technique. Results: Assessment of the diagnostic performance of serum GP73 and serum AFP in the present study in diagnosis of HCC revealed that serum GP73 at cutoff of 11.1 ng/mL showed a diagnostic sensitivity of 82.5%, specificity 70%, positive predictive value 78.6%, negative predictive value 75% and the area under the curve (AUC) was 0.8025, Regarding serum AFP at cutoff 320ng/mL showed the diagnostic sensitivity of 79.41%, specificity 60 %, PPV 65.9%%, NPV 75 %, AUC 0.766, This proved the superiority of GP73 estimation over AFP assay in cases of HCC, Conclusion: Serum GP73 had an overall performance better than AFP in detection of HCC in patients with chronic HCV related liver disease so it can be used in diagnosis of HCC.

Keywords

Article Analytics

References

  1. Abdu Allah A, Mohammed K and Al-Azhary N. (2013): Endoglin: A Novel Biomarker in Assessment of Liver Fibrosis. Research Journal of Pharmaceutical, Biological and Chemical Sciences; 4(1): 1076-1083.
  2. Bachert C, Fimmel C and Linstedt AD (2007): Endosomal trafficking and proprotein convertase cleavage of cis Golgi protein GP73 produces marker for hepatocellular carcinoma. Traffic; 8:1415-1423.
  3. Braicu C, Burz C, Neagoe I B, et al. (2009): hepatocellular carcinoma: tumorigenesis and prediction markers.Gastroenterol. Res.; 2(4): 191-199.
  4. Change S, Kim SH, Lim HK, et al. (2008): Needle tract implantation after percutaneous interventional procedures in hepatocellular carcinomas: lessons learned from a 10-year experience, Korean J. Radiol.; 9:268-274.
  5. Fimmel CJ and Wright L (2009): Golgi protein 73 as a biomarker of hepatocellular cancer: Development of a quantitative serum assay and expression studies in hepatic and extrahepatic malignancies. Hepatol.; 49: 1421-1423.
  6. Gambarin-Gelwan M, Wolf DC, Shapiro R, et al. (2000): Sensitivity of commonly available screening tests in detecting hepatocellular carcinoma in cirrhotic patients undergoing liver transplantation. Am J Gastroenterol; 95: 1535-1538.
  7. Gomaa AI, Khan SA, Leen ELS, et al. (2009): Diagnosis of hepatocellular carcinoma. World J Gastroenterol; 15(11): 1301-1314.
  8. Gu Y, Chen W, Zhao Y, et al. (2009): Quantitative analysis of elevated serum Golgi protein-73 expression in patients with liver diseases.Ann Clin Biochem; 46: 38-43.
  9. Hakamada K, Kimura N, Morohashi H, et al. (2008): Des-gamma-carboxy prothrombin as an important prognostic indicator in patients with small hepatocellular carcinoma.World J Gastroenterol , 7; 14(9): 1370-1377.
  10. Hu JS, Wu DW, Liang S, et al. (2010): GP73, a resident Golgi glycoprotein, is sensibility and specificity for hepatocellular carcinoma of diagnosis in a hepatitis B‑endemic Asian popu?lation. Med Oncol ;27: 339‑345.
  11. Johnson M (2006): Amino acids and proteins. In: Teitz fundamentals of clinical chemistry, (6th ed), C. A. Burtis, E. R. Ashwood, and D. E. Bruns, ( Eds). W. B Saunders Co. Philadelphia, pp: 286-317.
  12. Kew MC (2002): Hepatic tumors and cysts. In: Gastrointestinal and Liver Disease. Feldman M, Friedman LS and Sleisenger MH (eds.), WB Saunders, Philadelphia, p. 1579.
  13. Laffan M (2006): Laboratory control of anticoagulant, thrombolytic and anti-platelet therapy. In: Dacie and Lewis practical hematology, (10th ed), S. M. Lewis, B. J. Bain, I. Bates (Eds). Churchill livingstone co. philadelphia, pp: 465-523.
  14. Liu T, Yao M, Liu S, et al. (2017): Serum Golgi protein 73 is not a suitable diagnostic marker for hepatocellular carcinoma. Oncotarget.7; 8(10):16498-16506.
  15. Mao Y, Yang H, Xu H, et al. (2010): Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma. Gut ; 10: 1-7.
  16. Marrero JA (2013): Multidisciplinary management of hepatocellular carcinoma: where are we today? Semin Liver Dis; 33 Suppl 1:S3-10.
  17. Marrero JA, Romano PR, Nikolaeva O, et al. (2005): GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. J Hepatol ;43: 1007‑1012.
  18. Ozkan H, Erdal H, Tutkak H, et al. (2011): Diagnostic and prognostic validity of Golgi protein 73 in hepatocellular carcinoma. Diagestion.; 83: 83-88.
  19. Panteghini M (2006): In: Teitz fundamentals of clinical chemistry, (6th ed), C. A. Burtis, E. R. Ashwood, and D. E. Bruns, ( Eds). W. B saunders Co. Philadelphia; pp: 317-337.
  20. Riener MO, Stenner F, Liewen H, et al. (2009): Golgi Phosphoprotein 2 (GOLPH2) expression in liver tumors and its value as Serum marker in hepatocellular carcinomas.Hepatol. ; 49(5):1602-1609.
  21. Saar B and Kellner WF (2008): Radiological diagnosis of hepatocellular carcinoma. Liv. Int.; 28(2):189-199.
  22. Sangiovanni A, Romeo R, Prati GM, et al. (2007): Serum expression of lectin reactive alpha-fetoprotein, des-gammacarboxy prothrombin, golgi protein-73 antigen and antibody, for the diagnosis of hepatocellular carcinoma. HEPATOLOGY; 46(Suppl):406A.
  23. Sherlock S and Dooley J (2002): Diseases of the liver and biliary system. 11th ed. , Blackwell S.C. , Oxford London, Eninburgh, Chapter 31, page, 537 ? 561.
  24. Stefaniuk P, Cianciara J, Wiercinska D, et al. (2010): Present and future possibilities for early diagnosis of hepatocellular carcinoma World J Gastroenterol. 28; 16(4): 418-424.
  25. Tian L, Wang Y, Xu D, et al. (2010): Serological AFP/ golgi protein 73 could be a new diagnostic parameter of hepatic diseases. Int JCancer Dec 7.
  26. Trevisani F, D?Intino PE, Morselli-Labate AM, et al. (2001): Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol ; 34: 570-575.
  27. Wang M, Long RE, Comunale MA, et al. (2009): Novel fucosylated biomarkers for the early detection of hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev ;18: 1914‑1921.
  28. Yang J, Li J, Dai W, et al. (2015): Golgi protein 73 as a biomarker for hepatocellular carcinoma: A diagnostic meta-analysis. Exp Ther Med.; 9(4):1413-1420.
  29. Zhou Y, Li L, Hu L, et al. (2011): Golgi phosphoprotein 2 (GOLPH2/GP73/GOLM1) interacts with secretory clusterin. Mol. Biol. Rep.; 38: 1457?1462.

How to Cite This Article

Magdy Abdel-Mawgood Gad, Tamer. E. Eleraky, Amira Mohamed Abdelrahman and Mohamed Adel Elsayed Darahem. (2017); SERUM GOLGI PROTEIN 73 IN PATIENTS WITH HEPATOCELLULAR CARCINOMA., Int. J. of Adv. Res., 5 (12), 184-192, ISSN 2320-5407. DOI: https://doi.org/10.21474/IJAR01/5954

Corresponding Author

Mohamed Adel Elsayed Darahem
Department ofHepatology, Gastroenterology and Infectious diseases, Ministry of health.
Creative Commons Attribution 4.0 This work is licensed under a Creative Commons Attribution 4.0 International License.